This Million Targets Drug: A $7M Bet on a CNS Breakthrough
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
A concise guide to spotting tax-friendly dividend ETFs, including key metrics and quick tips to boost after-tax performance.
22,830 articlesA focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
A headline about Palantir and a high-stakes defense AI plan could reshape risk and opportunity. This guide breaks dow...
Plug Power has captured attention as its revenue growth accelerates amid a reshaped hydrogen market. This article bre...
Ripple pushes deeper into institutional finance as banks sign on to new settlement rails, even as XRP traders retreat...
Software shares rebound after April troughs, lifting the IGV ETF. CrowdStrike's upcoming results are the main catalys...
New analysis shows the Trump family generated roughly $2.3 billion in pretax crypto income from late 2024 through Apr...
A sweeping shift shows crypto institutional flows turning negative, with about $8 billion pulled from BTC ETFs, stabl...
Looking for breakout growth stocks hold potential for the next decade? This article breaks down three durable picks, ...
Matrixport’s fear index shows mounting pessimism as Bitcoin whipsaws in a volatile market. While downside risk remain...
Explore ibotta (ibta) 2025 earnings projections, including revenue drivers, user growth, and profitability timelines....
Dogecoin has volatile history and meme-driven momentum. Here are three grounded reasons I won’t be buying in 2026, pl...
Oil prices surge on supply concerns, pushing the S&P 500 lower as investors rotate into energy names. This stock mark...